Huatai Securities Injects $15M Into Chinese Genetic, Protein Engineering Tech Start-Up

Login to View

Abiochem Biotechnology Co Ltd, a Chinese biotech start-up specialized in genetic and protein engineering technologies, has raised over RMB100 million (US$14.89 million) in a new round of financing led by Huatai Zijin Investment, a wholly-owned investment subsidiary of Chinese securities group Huatai Securities, according to a statement released on Wednesday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in